An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years.
Anti-MDA5 antibody-positive patients with clinically amyopathic dermatomyositis (CADM) are at high risk of developing rapidly progressive interstitial lung disease (ILD), which is associated with a high mortality rate. Approximately half of the patients with ILD recover; however, the long-term clinical course of these patients has not been fully reported and is not completely understood. This report describes the atypical clinical course of an anti-MDA5 antibody-positive CADM patient who experienced three deteriorations of ILD in 9 years. These findings indicate that the ILD in anti-MDA5 antibody-positive patients may not only be rapidly progressive, but may also be chronic and recurrent.
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Japan.
Yuki
Y
Sato
Kojiro
K
Otsuka
Koji
K
Tamai
Yuichiro
Y
Ono
Yasuhito
Y
Hamaguchi
Keisuke
K
Tomii
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D053487:DEAD-box RNA Helicases / Q000276:immunology; D003882:Dermatomyositis / Q000150:complications / Q000276:immunology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D000072640:Interferon-Induced Helicase, IFIH1 / Q000276:immunology; D017563:Lung Diseases, Interstitial / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; C501597:CADM-140 peptide, human; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D053487:DEAD-box RNA Helicases; D000072640:Interferon-Induced Helicase, IFIH1